> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CalciMedica Advancing Covid-19 Drug Trial
- URL: https://www.fdaweb.com/calcimedica-advancing-covid-19-drug-trial/
- Published: 2020-05-21T12:00:00.000Z
- Updated: 2026-09-14T16:15:39.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146837

CalciMedica says it is transitioning an ongoing randomized open-label study to a blinded placebo-controlled trial for Auxora (formerly called CM4620-IE) in patients with Covid-19 pneumonia. The move was recommended by FDA after reviewing a submission of a recent interim analysis of Auxora in patients suffering from severe Covid-19 pneumonia. The interim analysis was conducted by CalciMedica following an Independent safety review committee recommendation to continue the study, the company says.  

Auxora is described by CalciMedica as a potent and selective small molecule calcium release-activated calcium (CRAC) channel inhibitor that prevents CRAC channel overactivation. It has been shown that CRAC channel overactivation can cause pulmonary endothelial damage and cytokine storm in Covid-19, it says.